Brought to you by 
MedImmune licenses Pfizer’s tremelimumab
05 Oct 2021
Executive Summary
Pfizer Inc. has granted AstraZeneca PLC’s biologics division MedImmune LLC global rights to develop its oncology compound tremelimumab (CP675206). Pfizer retains rights for use with specific types of combination therapies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune licenses Pfizer’s tremelimumab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice